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Abstract Type 2 diabetes mellitus (T2DM) inﬂuences
bone metabolism, but the relation of T2DM with bone
mineral density (BMD) remains inconsistent across studies.
The objective of this study was to perform a meta-analysis
and meta-regression of the literature to estimate the dif-
ference in BMD (g/cm
2) between diabetic and non-diabetic
populations, and to investigate potential underlying
mechanisms. A literature search was performed in PubMed
and Ovid extracting data from articles prior to May 2010.
Eligible studies were those where the association between
T2DM and BMD measured by dual energy X-ray absorp-
tiometry was evaluated using a cross-sectional, cohort or
case–control design, including both healthy controls and
subjects with T2DM. The analysis was done on 15
observational studies (3,437 diabetics and 19,139 controls).
Meta-analysis showed that BMD in diabetics was signiﬁ-
cantly higher, with pooled mean differences of 0.04 (95%
CI: 0.02, 0.05) at the femoral neck, 0.06 (95% CI: 0.04,
0.08) at the hip and 0.06 (95% CI: 0.04, 0.07) at the spine.
The differences for forearm BMD were not signiﬁcantly
different between diabetics and non-diabetics. Sex-strati-
ﬁed analyses showed similar results in both genders. Sub-
stantial heterogeneity was found to originate from
differences in study design and possibly diabetes deﬁnition.
Also, by applying meta-regression we could establish that
younger age, male gender, higher body mass index and
higher HbA1C were positively associated with higher BMD
levels in diabetic individuals. We conclude that individuals
with T2DM from both genders have higher BMD levels,
but that multiple factors inﬂuence BMD in individuals with
T2DM.
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Introduction
Osteoporosis and diabetes are both common human dis-
eases. Albright and Reifenstein [1] reported their coexis-
tence in 1948, but hitherto the association between them
remains unclear. Due to the different pathogenesis of type
1 and type 2 diabetes mellitus (T2DM), it is not surprising
that there is no uniform entity of diabetic bone disease as
such. While decreased bone mineral density (BMD) has
consistently been observed in type 1 diabetes mellitus
patients [2, 3], studies on BMD investigated in T2DM
showed contradictory results with higher, lower or similar
values in comparison with healthy control subjects [4–7].
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ences in study design, BMD measurement technology,
differences in site of BMD examination, selection of
patients, and presence or absence of complications.
It is well known that advanced age is a risk factor for
bone loss and osteoporosis [8, 9]. Some of the attributed
mechanisms include increased production of inﬂammatory
cytokines and cellular components, incremental osteoclast
precursors generation and decreased bone preservation due
to gonadal failure resulting in lower tissue production of
sex steroids [10]. Advanced age is also associated with
increased fall frequency, lack of exercise, use of drugs that
negatively inﬂuence bone metabolism and renal function
such as drugs prescribed for diabetes and hypertension.
Gender also appears to have an important effect on the
relation between BMD and T2DM. Barrett-Connor [11]
found that older women with T2DM had higher BMD
levels at all sites compared to those with normal glucose
tolerance, but this effect was not observed in men. It has
also been suggested that obesity and hyperinsulinemia can
lead to lower bone turnover in diabetic women [7, 12], so
that the adverse effects of estrogen deﬁciency on bone
mass are attenuated and delayed after menopause.
Many studies have shown a difference in population
characteristics between type 2 diabetic patients and healthy
controls [6, 11, 13, 14]. Diabetic study participants tend to
have a higher body mass index (BMI) or weight, increased
insulin levels, less physical exercise, higher alcohol con-
sumption and they usually smoke more. The use of
diuretics is more common in diabetes. These characteristics
might inﬂuence bone metabolism independently of diabe-
tes. Paradoxically, an increased risk of osteoporotic frac-
ture in T2DM has been repeatedly demonstrated and this
was independent of BMD [13, 15]. This association with
fracture adds uncertainty around the actual association
between diabetes mellitus and BMD.
The aim of our study was to perform meta-analysis of
published articles exploring differences between type 2
diabetics and healthy individuals in BMD levels measured
at four anatomical sites. In addition, we evaluated factors
inﬂuencing BMD variation like sex, age, BMI and glucose
control (HbA1c levels) for which a meta-regression was
performed to evaluate potential mechanisms by which
T2DM inﬂuences BMD variation.
Materials and methods
Search strategy
A systemic search for all literature that was published in
May 2010 or earlier was performed using Pubmed and
Ovid online (1950 to present with daily update). The search
used MeSH terms ‘‘diabetes mellitus’’ and (‘‘osteoporosis’’
OR ‘‘bone density’’ or ‘‘bone mass’’).
Study selection
Studies were considered eligible for the meta-analysis if (1)
they evaluated the association between T2DM and BMD,
(2) they were of a cross-sectional, cohort or case–control
design, (3) they included healthy subjects without DM as
controls, (4) they reported gender-stratiﬁed statistics on
both individuals with and without T2DM, (5) BMD was
measured by dual energy X-ray absorptiometry (DXA) and
(6) BMD measurements were expressed as an absolute
value in g/cm
2. In the cases that more than one article
presented data from the same study population, the study
with more complete reporting of data was selected.
Studies in nonhuman populations, review articles,
experimental studies, case reports or studies that lacked
controls, studies on type 1 or other types of DM, studies
that had no clear deﬁnition of T2DM, studies that measured
BMD measured by computed tomography, ultrasound or
single X-ray absorptiometry were all regarded as ineligible.
Only published results were used and papers in all lan-
guages were considered. We supplemented electronic
searches by hand-searching reference lists of relevant
articles and reviews. The abstracts and titles of primitive
collections were initially browsed and all observational
studies were extracted. Potentially relevant articles were
then considered by double checkout. Disagreements were
resolved by discussion between at least two reviewers.
Data
Quality-scoring varies in meta-analyses of observational
studies and no criteria have been internationally accepted
to date. Consequently, we appraised each article included
in this analysis with the guidelines of the MOOSE group
[16]. Some key points were: clear deﬁnition of study
population, clear and internationally accepted criteria of
diagnosing diabetes, description of the coefﬁcient of vari-
ation for BMD measurements, consecutive selection of
cases, random selection of controls and identiﬁcation of
important confounders. We required that at least 2 studies
per site-speciﬁc BMD outcome should be available to
perform a meta-analysis.
Mean and its standard deviation (SD) of BMD mea-
surements at the calcaneus, femoral neck, total hip, spine
and forearm in both diabetics and non-diabetics were
extracted to explore the pooled mean difference estimation.
If repeated measurements were available in cohort studies
we extracted only the measurements at baseline (or the
earliest available measurement) as being a cross-sectional
study. The mean and standard deviation had to be
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between different studies. If there were statistically sig-
niﬁcant age differences between patients and controls and
the age-adjusted mean and deviation could be found, these
data were used; if these were not found the study was
excluded. In addition, we performed meta-analysis
including the maximally adjusted estimates from studies
where available. If sample size of either group in com-
parison was less than 30, it was not used in our analysis.
Gender was considered to be a determinant for subgroup
analysis.
If studies lacked SD estimates but provided P value,
standard error (SE), conﬁdence interval (CI) that related to
the mean difference, we estimated SDs using the following
methods [17]:
1. From SE to SD: the following formula was used:
SD ¼ SE ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
Ncase
þ 1
Ncontrol
q ;
2. From CI to SD: SE = (upper limit - lower limit)/3.92
(if 95% CI), then replaced in formula.
3. From P value to SD: the corresponding t-value
according to P value was obtained from a table of
the t-distribution with the degrees of freedom given by
Ncase ? Ncontrol - 2 (where Ncase,N control are the
sample sizes); then, assuming SE ¼ MD
t (where MD
is mean difference between case and control); we
ﬁnally replaced SE in the formula:
SD ¼ SE ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
Ncase
þ 1
Ncontrol
q (where SD is the average of
the SDs of the case and control arms);
Analyses
The weighted mean difference estimates of BMD in g/cm
2
comparing diabetes with controls were calculated as Der-
Simonian and Laird estimators using random effects
models. As secondary analyses inverse variance ﬁxed
effect models were applied. Publication bias was tested
using funnel plots. Tests for heterogeneity were performed
by applying the Cochran Q test and estimating the degree
of inconsistency index (I
2)[ 18]. Sources of heterogeneity
were investigated by sensitivity analyses stratifying on
study design, by excluding studies: on Asian populations,
presenting large differences in BMI between cases and
controls, and/or having BMD measurements assessed by
different densitometers. All analyses were conducted with
the use of Review Manager, version 5.0 (Revman, The
Cochrane Collaboration; Oxford, UK) and Comprehensive
Meta-analysis version 2 (Biostat, Inc., Englewood, USA).
To estimate the effects of gender, age, BMI and HbA1C on
the BMD measured at the different sites a meta-regression
analysis was performed using STATA 11.0 (StataCorp LP,
USA).
Results
Figure 1 shows a ﬂow diagram describing the study
selection process. The initial search yielded 1,161 research
reports, of which 222 were excluded for having the same
title or authors; 788 were excluded due to not eligible study
design (including non-human studies, review articles, case
reports, comment, letter, experimental study, and/or frac-
ture-only outcome). Additional 109 studies were found
irrelevant to the original research question and excluded
because the disease of interest was either type 1 or gesta-
tional DM (81 studies); or for not measuring bone mass
using DXA, i.e. by single X-ray absorptiometry, CT or
ultrasound (28 studies). Of the 42 remaining studies, 11
either lacked non-diabetic controls at all or did not report
means and standard deviations in non-diabetic controls
[19–29]. In addition, six studies had small sample sizes
1161 studies found 
(pubmed 490; ovid online 671) 
222 excluded for same title or author 
overlap 
939 studies selected 
on the basis of title/abstract: 
-  788 excluded for study design 
(non-human, review, case report, 
comment, letter, experimental study, 
or only evaluating fracture outcomes) 
-  109 irrelevant to the current study: 
- 81 excluded for only exploring 
type 1 DM or gestational DM; 
    -  28 excluded for measuring 
bone mineral density by X-ray, 
computerized tomography or 
ultrasound 
42 relevant studies selected for 
evaluation by reading full text 
28 studies excluded on 1 or more 
criteria: 
- 11 lacked non-diabetes control; 
- 2 no gender-stratified statistics; 
-   6 small sample size (<30); 
-   2 contained same population; 
- 3 large age difference between 
groups but no age-adjusted 
values; 
-   1 presenting overmatched data; 
-   4 studies not obtainable 
-   1 meeting criteria but not 
meta-analyzed since was only 
study with calcaneal BMD 
1 additional study included by 
manual-search 
Total 15 observational studies   
included  
Fig. 1 Flow diagram of the study-selection process. DM diabetes
mellitus, CT computed tomography, US ultrasound
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123(n\30) in either group of comparison [30–35]. The study
population of two studies was used in follow-up reports [4,
36]. In three studies there was a big age difference between
individuals with diabetes and those without diabetes, but
the investigators did not adjust for it [37–39]. One study
matched cases and controls by age and BMI and presented
data only on post-matching [40]. The original articles of
four articles could not be retrieved [41–44]. All of these
aforementioned studies were excluded. One study cited as
reference in one of the research reports was traced and
satisﬁed the inclusion criteria [45]. In one research report
the results of gender-speciﬁc BMD analyses was men-
tioned, but not listed in detail [14]. We contacted the
researchers and were able to retrieve this information. The
study of Perez et al. [46] found a signiﬁcantly increased
calcaneal BMD in female but not in males subjects with
diabetes. No meta-analysis was attempted for this site since
this was the only study that evaluated BMD at the calca-
neus. Since no SD’s for male comparison groups could be
retrieved for the paper by Barrett-Connor et al. we were not
able to include these results for men. As we extracted only
a single measure and didn’t examine repeated measure-
ments, cohort studies were analyzed as cross-sectional
using the baseline or earliest available measurement. A
total of 15 observational studies (9 case–control, 6 cross-
sectional) were included in our meta-analysis (3,437 dia-
betics and 19,139 controls) [5–7, 11, 12, 14, 45, 47–54].
Table 1 indicates the quality evaluation of all studies. We
did not observe indication of publication bias on the Funnel
Plots (data not shown), with the effect magnitude of larger
studies being closer to and smaller studies largely equally
distributed at both sides of the summary estimate.
Table 2 shows study population characteristics and the
reported effect of covariates on the association between
BMD and T2DM. Out of ﬁve studies performed in the US,
one had included Mexican–American women [6] and one
hadwhiteandblackparticipants[51].Onestudywasdonein
Eastern Asia [7] and another two in Eastern Europe [53, 54].
The remaining eight studies collected data in Western Eur-
ope and Oceania. Participants in all study populations were
aged 25 years and over and approximately 70 % were mid-
dle-aged or older. In addition, Table 2 shows that the most
common covariates considered by the studies were BMI or
weight, cigarette smoking, alcohol use, physical activity,
diuretic use, calcium intake, estrogen use (women), meno-
pause status (women), age at menarche (women), insulin
level, HbA1C and alkaline phosphatase. Table 3 shows the
population characteristics of the source studies by gender.
Table 1 Aspects of quality and design of the included articles
Reference Study
design
Clear deﬁnition
of study
population
Clear criteria
of diagnosing
diabetes
Precise control
(CV) for BMD
measurement
Consecutive
selection
of cases
Random
selection
of controls
Identiﬁcation
of important
confounders
Barrett-Connor [11] Cross-sectional Yes WHO criteria NA Yes Yes Yes
Sosa [47] Case–control Yes NDDG criteria
(Canada)
Yes No No (age-
matched)
Yes
Tuominen [48] Case–control Yes NA (hospital
database)
NA Yes Yes Yes
Kao [6] Cross-sectional Yes WHO criteria,
self-reported
Yes Yes Yes Yes
Dennison [49] Cross-sectional Yes OGTT Yes Yes Yes Yes
Bridges [50] Case–control Yes NA (hospital
database)
NA No Yes Yes
Gerdhem [12] Cross-sectional Yes Self-reported Yes Yes Yes Yes
de Liefde [14] Cross-sectional Yes Screening (OGTT),
drug use
Yes Yes Yes Yes
Majima [7] Case–control Yes OGTT NA Yes Yes Yes
Schwartz [51] Case–control Yes FPG, OGTT,
self-reported
Yes Yes Yes Yes
Bonds [45] Cross-sectional Yes Self-reported,
drug use
NA Yes Yes No
Rakic [52] Case–control Yes WHO criteria Yes Yes No (age-,
sex-matched)
Yes
Hadzibegovic [53] Case–control Yes NA NA Yes Yes Yes
Anaforoglu [54] Case–control Yes NA (hospital
database)
NA Yes No (age-
matched)
Yes
Yaturu et al. [5] Case–control NA NA Yes Yes Yes Yes
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123Table 4 presents BMD levels in diabetics and non-dia-
betics at four skeletal sites across the different studies, also
including subgroup analysis by gender. At the femoral
neck, all studies except for Yaturu et al. [5] and Majima [7]
found a higher BMD in subjects with diabetes. At the total
hip, all referred studies showed signiﬁcantly higher BMD
in diabetics. At the lumbar spine, almost all of the studies
reported a higher BMD in diabetics. These differences
were statistically signiﬁcant in the vast majority. At the
forearm there were no signiﬁcant differences between
diabetics and non-diabetics in all analyses. No major dif-
ferences between genders were found.
Some reports concluded that the association remained
signiﬁcant despite the fact that the effect size decreased
remarkably after correcting for aforementioned covariates
[6, 11, 12, 14, 48, 54]. In others, the association disap-
peared or even shifted in the opposite direction after
adjustment for covariates, particularly in the case of BMI
or weight [5, 49, 51, 52]. We performed meta-analysis for
maximally adjusted estimates where available, which did
not signiﬁcantly alter previously calculated mean differ-
ences. Nearly all studies found that BMI was positively
correlated with BMD. There was some evidence suggesting
that other factors such as insulin levels also had a positive
correlation with BMD [7]. In contrast, HbA1c levels had
positive [7], negative [51] or no correlation [50] with
BMD. In a follow-up study, Schwartz [51] found that after
adjustment for covariates white women with T2DM lost on
average more BMD per year than those without DM.
Table 5 shows meta-analysis results of pooled mean
differences and corresponding 95% conﬁdence intervals of
BMD values between diabetic and non-diabetic individu-
als. In the pooled meta-analyses the differences were 0.04
(95% CI: 0.02, 0.05) at the femoral neck, 0.06 (95% CI:
0.04, 0.08) at the hip, 0.06 (95% CI: 0.04, 0.07) at the
spine, and -0.003 (95% CI: -0.02, 0.02) at the forearm,
respectively. In the sex-stratiﬁed analysis these differences
were most pronounced for females, being 0.04 (95% CI:
0.03, 0.06), 0.07 (95% CI: 0.04, 0.11), 0.07 (95% CI: 0.05,
0.09), 0.01 (95% CI: -0.02, 0.03) at the femoral neck, hip,
spine, and forearm, respectively. In males these differences
were statistically signiﬁcant at the hip 0.04 (95% CI: 0.01,
0.08) and spine 0.05 (95% CI: 0.02, 0.07). The meta-
analysis result in males was non-signiﬁcant at the femoral
neck 0.03 (95% CI: 0.00, 0.05) and forearm -0.01 (95%
CI: -0.04, 0.02). This information is displayed in more
detail in the forest plots of Figs. 2, 3, 4, and 5.
The heterogeneity (Q) tests showed signiﬁcant differ-
ences between individual studies (P\0.01) at all sites in
the total group and sex-speciﬁc analyses (Table 5). Still,
point estimates and statistical signiﬁcance from ﬁxed
effects models were very similar to those derived from
random effects models. We further performed sensitivity
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123analyses to identify potential sources of the observed het-
erogeneity. Subgroup analyses per study design (case–
control/cross-sectional) showed that case–control studies
had effect estimates with larger variation around the pooled
estimate thereby increasing the heterogeneity. For the
femoral neck BMD analysis the largest source of hetero-
geneity was traced back to one study by Yaturu et al. [5].
This study include only men and observed a positive
relation with lumbar spine and a negative one for femoral
neck; after removing this study the I
2 statistic dropped from
81 to 57 %. Another study in Asians also displayed esti-
mates in the opposite direction for different outcomes
though not signiﬁcant [7]. Removing seven studies with
signiﬁcantly different BMI between diabetes and non-dia-
betes [5, 12, 14, 47, 50, 51, 54] or six studies that did not
use a densitometer manufactured by Hologic incorporation
(USA) [5, 12, 14, 48, 50] from the analyses showed no
signiﬁcant inﬂuence on the observed heterogeneity, except
for the femoral neck BMD analysis, but this was largely
attributable to the large heterogeneity brought in by the
Yaturu et al. study [5].
The results of a meta-regression on BMD by sex, age,
BMI and glucose control (HbA1c levels) is presented in
Table 6 for individuals from the diabetic group of the
studies. Being a woman was associated with signiﬁcantly
lower BMD levels at all four anatomical sites, as compared
to men. Age was negatively associated with BMD at hip
but positively at the lumbar spine. Higher BMI was a
strong determinant of higher BMD at the femoral neck and
lumbar spine, with no apparent effect on forearm BMD.
Higher HbA1C levels (reﬂecting lesser glucose control)
resulted in higher BMD at the femoral neck and total hip.
Discussion
Our study provides insights into the inconsistently reported
relationship between T2DM and BMD. In line with what is
suggested by the majority of reviewed studies our meta-
analysis concluded that overall individuals with T2DM
have about 25–50 % SD higher BMD compared to non-
diabetic control subjects.
In this study we found no strong evidence for skeletal
site speciﬁcity of this association. Subjects with T2DM had
elevated BMD at the femoral neck, hip, and spine. No
major differences in BMD at the forearm were seen but
there are no obvious biological reasons we can attribute to
them. This lack of association with forearm BMD may be
the consequence of limited sample size. We also found no
strong evidence suggesting there is sex-speciﬁcity in the
observed BMD differences between diabetics and non-
diabetics. BMD differences seem larger in women than in
men but power limitations can also play a role. We did ﬁnd
considerable heterogeneity inﬂuencing the association as
reﬂected by a high I
2 statistic. This large heterogeneity
could most probably stem from a large variation in types of
study design, diagnostic deﬁnitions and individual char-
acteristics that were not considered by each study. We did
sensitivity analyses trying to ﬁnd sources of heterogeneity
and concluded that study design and Asian ethnicity are a
likely, but not sufﬁcient sources to explain the observed
heterogeneity. In contrast, differences in DXA manufac-
turers and levels or correction for BMI do not seem to be an
important source of heterogeneity.
Our study has limitations. We procured including all
eligible studies to the best of our capacities but at least four
Table 3 Population characteristics of the source studies by gender
Study Female Male
Age
(years)
BMI
(kg/m
2)
HbA1c
(%)
Serum
creatine
(lmol/L)
Disease
duration
(years)
Age
(years)
BMI
(kg/m
2)
HbA1c
(%)
Serum
creatine
(lmol/L)
Disease
duration
(years)
Barrett-Connor [11] 76.0 26.3 6.7 99.7 NA 76.0 26.3 6.7 99.7 NA
Tuominen [48] 63.3 25.3 9.8 NA NA 63.3 25.3 9.8 NA NA
Kao [6] 54.3 33.0 NA NA NA 54.3 33.0 NA NA NA
Dennison [49] 64.8 26.6 NA NA NA 64.8 26.6 NA NA NA
Bridges [50] 62.8 31.4 8.9 NA 10.1 62.8 31.4 8.9 NA 10.1
de Liefde [14] 69.6 25.8 NA 96.2 NA 69.6 25.8 NA 96.2 NA
Majima [7] 62.8 23.6 7.8 66.3 NA 62.8 23.6 7.8 66.3 NA
Schwartz [51] (white) 73.7 NA 7.2 NA 7.4 73.7 NA 7.2 NA 7.4
Schwartz [51] (black) 74.0 NA 8.2 NA 9.5 74.0 NA 8.2 NA 9.5
Rakic [52] 66.0 29.0 7.4 94.0 8.7 66.0 29.0 7.4 94.0 8.7
Yaturu et al. [5] 67.5 30.1 NA 106.1 NA 67.5 30.1 NA 106.1 NA
Association between bone mineral density and type 2 diabetes mellitus 325
123Table 4 Unadjusted/age-adjusted, gender-speciﬁc BMD in patients with diabetes and controls per skeletal site (mean ± SD g/cm
2)
Reference Female Male
Sample
size (case/
control)
Diabetes Non-diabetes P value Sample
size (case/
control)
Diabetes Non-diabetes P value
Skeletal site of BMD measurement: femoral neck
Barrett-Connor [11] 37/237 0.664 ± 0.118
a 0.610 ± 0.118
a \0.01 41/139 0.747 ± NA 0.744 ± NA
a NS
Sosa [47] 47/252 0.756 ± 0.146 0.737 ± 0.115 NS
Tuominen [48] 34/240 0.881 ± 0.143 0.872 ± 0.131 NS
Dennison [49] 32/278 0.830 ± 0.120 0.740 ± 0.110 \0.0001 33/349 0.900 ± 0.130 0.840 ± 0.110 0.03
Gerdhem [12] 67/961 0.820 ± 0.120 0.740 ± 0.110 \0.0001
de Liefde [14] 326/3,049 0.859 ± 0.148 0.826 ± 0.134 \0.0001 254/2,195 0.946 ± 0.149 0.914 ± 0.136 0.0003
Majima [7] 81/54 0.620 ± 0.153 0.660 ± 0.118 NS 64/41 0.759 ± 0.137 0.767 ± 0.108 NS
Schwartz [51] (white) 97/383 0.670 ± 0.110 0.640 ± 0.100 \0.05 153/395 0.800 ± 0.120 0.760 ± 0.130 \0.05
Schwartz [51] (black) 125/225 0.790 ± 0.130 0.730 ± 0.130 \0.05 105/169 0.890 ± 0.140 0.830 ± 0.120 \0.05
Rakic [52] 86/86 0.808 ± 0.153 0.722 ± 0.103 \0.001 108/108 0.851 ± 0.128 0.802 ± 0.129 0.01
Hadzibegovic [53] 130/166 0.870 ± 0.132 0.832 ± 0.134 \0.05
Anaforoglu [54] 206/61 0.770 ± 0.110 0.730 ± 0.120 0.280
Yaturu et al. [5] 735/3,458 0.892 ± 0.244
b 0.930 ± 0.176
b \0.0001
Skeletal site of BMD measurement: total hip
Schwartz [51] (white) 97/383 0.790 ± 0.120 0.750 ± 0.120 \0.05 153/395 0.950 ± 0.130 0.930 ± 0.140 \0.05
Schwartz [51] (black) 125/225 0.910 ± 0.150 0.840 ± 0.150 \0.05 105/169 1.070 ± 0.150 1.000 ± 0.130 \0.05
Bonds [45] 469/5,916 0.900 ± 0.160 0.840 ± 0.140 \0.01
Rakic [52] 86/86 0.993 ± 0.173 0.848 ± 0.118 \0.001 108/108 1.060 ± 0.156 1.013 ± 0.158 0.038
Skeletal site of BMD measurement: spine
Barrett-Connor [11] 37/237 0.962 ± 0.225
a 0.859 ± 0.225
a \0.01 41/136 1.081 ± NA
a 1.069 ± NA
a NS
Sosa [47] 47/252 0.898 ± 0.137 0.892 ± 0.138 NS
Kao [6] 98/285 1.071 ± 0.188
b 1.011 ± 0.236
b \0.01 55/162 1.057 ± 0.222
b 1.063 ± 0.255
b NS
Dennison [49] 32/278 1.070 ± 0.180 0.940 ± 0.180 0.0001 33/349 1.160 ± 0.120 1.070 ± 0.160 0.005
Gerdhem [12] 67/961 1.070 ± 0.230 0.990 ± 0.190 0.0001
de Liefde [14] 327/3,052 1.084 ± 0.188 1.030 ± 0.179 \0.0001 255/2,205 1.196 ± 0.209 1.161 ± 0.196 0.007
Majima [7] 81/54 0.861 ± 0.193 0.831 ± 0.162 NS 64/41 0.972 ± 0.176 0.975 ± 0.108 NS
Bonds [45] 472/5,922 1.040 ± 0.190 0.970 ± 0.170 \0.01
Rakic [52] 86/86 1.031 ± 0.171 0.948 ± 0.152 \0.001 108/108 1.117 ± 0.176 1.102 ± 0.191 0.55
Hadzibegovic [53] 130/166 0.903 ± 0.165 0.824 ± 0.199 \0.001
Anaforoglu [54] 206/61 0.900 ± 0.160 0.870 ± 0.150 0.264
Yaturu et al. [5] 735/3,458 1.223 ± 0.217
b 1.149 ± 0.176
b \0.0001
Skeletal site of BMD measurement: forearm
Kao [6] 98/285 0.477 ± 0.079
b 0.463 ± 0.101
b NS 55/162 0.535 ± 0.096
b 0.547 ± 0.102
b NS
Bridges [50] 90/50 0.560 ± 0.097
c 0.560 ± 0.090
c NS
Majima [7] 81/54 0.493 ± 0.109 0.547 ± 0.095 \0.01 64/41 0.665 ± 0.092 0.721 ± 0.080 \0.05
Rakic [52] 86/86 0.540 ± 0.066 0.481 ± 0.068 \0.001 108/108 0.641 ± 0.062 0.627 ± 0.063 0.09
Hadzibegovic [53] 130/166 0.496 ± 0.065 0.485 ± 0.081 NS
Anaforoglu [54] 206/61 0.48 ± 0.050 0.49 ± 0.010 0.696
SD written as NA if neither exact P value, SE or CI was available
a Using the formula from P value to SD
b Using the formula from SE to SD
c Using the formula from CI to SD
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123studies were not able to be traced back. Sensitivity analyses
considering such studies did not essentially change our
results or conclusions. Variation in the deﬁnition of T2DM
was present across studies with some combining self-
reports and blood glucose tests, while others only used
blood glucose tests. Studies which relied either on self-
reports, population screening or which used register data
will be subject to potential disease misclassiﬁcation bias.
Similarly, differences in mode of diagnosis can affect the
prevalence of disease across studies and, hence, inﬂuence
the power for detecting BMD differences. Disease duration
can also be an important confounder, but uniform assess-
ment for this co-variable was not possible across studies.
Another drawback is that not all studies reported on or
adjusted for covariates. Yet another potential source for
heterogeneity that we could not control for are differences
in glucose control and prevalence of diabetic complica-
tions. Nevertheless, the meta-regression done for BMD on
the group of diabetic individuals across studies shows that
in addition to BMI, HbA1C levels also has a signiﬁcant
positive effect on BMD measured at any site.
Since May 2010 about 134 articles have been published
on the topic of which we could identify two that would
have met our inclusion criteria [55, 56]. These were studies
based on Chinese populations showing opposite results
with one concluding type 2 diabetics had higher BMD [55]
while the other [56] concluded diabetics had lower BMD
and higher risk of osteoporosis.
Mechanisms that might account for an association
between T2DM and increasing BMD are plentiful and
largely unclear. We discuss below from a clinical per-
spective the most important factors which can inﬂuence the
relationship between T2DM and BMD.
Obesity
Historically, overweight and hyperinsulinemia have been
postulated as two important features of T2DM which are
positively correlated with BMD. Yet, we saw that in a
considerable number of the included studies the correction
for BMI did not essentially modify the association. There
are several complex pathways by which obesity may
inﬂuence the relation between diabetes and BMD. Body
fatness may have an impact on the accuracy of DXA-based
BMD measures as demonstrated in obese diabetic patients
[57]. Yet, such measurement error should be negligible
considering that this phenomenon can either under or
overestimate the values and have been shown to have low
impact on the accuracy of the BMD measurement [58]. On
the other hand, adipose tissue releases a wide variety of
adipokines that have been implicated either directly or
indirectly in the regulation of bone remodeling [59].
Plasma leptin concentrations have been shown to be higher
in diabetic men than in healthy controls [60]. Leptin induces
bone growth by stimulating osteoblast proliferation and
differentiation in vitro [61–63] and it has also been shownto
inhibit osteoclastogenesis through reducing RANK/RANK-
ligand production and increasing osteoprotegerin [64, 65].
Other adipokines such as adiponectin and resistin are also
expressed in osteoblasts and osteoclasts [66, 67]. The
effects of these adipokines on bone metabolism remain
largely ambiguous but differentiation from mesenchymal
progenitor cells to osteo- or adipocytes may play a role [67–
70]. Some reports indicate that circulating adiponectin [71]
and resistin levels [72] are reduced in diabetes in line with a
recent report demonstrating that higher adiponectin levels
are associated with lower BMD [73].
Hyperinsulinemia
Some of the reviewed studies indicated that insulin levels
could mediate in part a positive association between T2DM
and elevated BMD. Individuals with T2DM usually have
an excess of insulin. Physiologically, insulin has an ana-
bolic effect on bone due to its structural homology to IGF-1
by interacting with the IGF-1 receptor which is present on
osteoblasts [74]. The IGF-1 signaling pathway is crucial for
bone acquisition [75]: both human and mouse studies have
demonstrated a signiﬁcant positive association between
IGF-1 and BMD [76, 77]. From this perspective it can be
hypothesized that hyperinsulinemia could have a mitogenic
effect on osteoblasts and their differentiation by stimulat-
ing the IGF-1 signaling pathway. Some indirect inﬂuences
of insulin on bone formation could possibly be mediated by
osteogenic factors such as amylin, osteoprotegerin, sex
steroids and sex hormone-binding globulin (SHBG).
Medication use
Thiazide use which is expected to be higher in diabetic
individuals has also been associated with higher BMD at
different skeletal sites [78, 79]. Similarly, statin use (also
more prevalent in diabetics) is also associated with higher
BMD [80, 81]. Nevertheless, several of the included
studies controlled for medication use, and thus it is unlikely
that this alone can explain the observed associations. On
the other hand medication use can well be a source of the
large heterogeneity observed in the meta-analysis.
Paradoxically increased fracture risk
For many of the aforementioned mechanisms resulting in
higher BMD it is rather difﬁcult to ﬁt their role in the
paradoxically increased fracture risk. It has been well
established that diabetic patients have impaired bone
healing after fracture [82]. This probably indicates a
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123compromise of both osteoclastic [82] and osteoblastic cell
lineages [83], and possibly also on bone remodeling.
Indeed, a recent study by Burghardt et al. [84] using high-
resolution peripheral quantitative computed tomography
(HR-pQCT) reported up to twice the cortical porosity
observed in type 2 diabetes patients as compared to con-
trols. The results of this pilot investigation provide a
potential explanation for the inability of standard BMD
measures to explain the elevated fracture incidence in
patients with T2DM presenting with higher BMD levels.
Speciﬁcally, the ﬁndings suggest that T2DM may be
associated with an inefﬁcient redistribution of bone mass
and insufﬁcient compensation for increased body mass,
which may result in impaired bending strength. In addition,
bone strength might be compromised through different
mechanisms,suchasincreasedproductionofnon-enzymatic
cross-linkswithincollagenﬁbers,accumulationofadvanced
glycationendproducts[85],higherserumglucoselevelsthat
can negatively inﬂuence bone matrix properties [86]o r
indirectly as a consequence of sarcopenia [87]. Finally,
patients with diabetes have increased fall risk, which can
arise as a consequence of sarcopenia, retinopathy and/or
neuropathy. Very recently, it has been shown how Type 2
diabetes underestimates the risk of fracture at a given BMD
Table 5 Pooled mean differences of BMD comparing diabetes with non-diabetes
Site Groups Number
of studies
Sample size
(case/control)
Mean difference
of BMD (g/cm
2)
P value Heterogeneity
I
2 (%) Q test P value
Femoral neck Total 12 2,720/12,707 0.04 [0.02, 0.05] \0.00001 83 \0.0001
Female 10 1,234/5,752 0.04 [0.03, 0.06] \0.00001 71 0.0002
Male 7 1,486/6,955 0.03 [0.00, 0.05] 0.09 87 \0.0001
Hip Total 3 1,143/7,282 0.06 [0.04, 0.08] \0.00001 78 0.0002
Female 3 777/6,610 0.07 [0.04, 0.11] \0.00001 82 0.001
Male 2 366/672 0.04 [0.01, 0.08] 0.007 63 0.07
Spine Total 12 2,833/17,677 0.06 [0.04, 0.07] \0.00001 66 \0.0001
Female 11 1,583/11,354 0.07 [0.05, 0.09] \0.00001 62 0.003
Male 6 1,250/6,323 0.05 [0.01, 0.07] 0.008 74 0.002
Forearm Total 6 918/1,013 -0.003 [-0.02, 0.02] 0.90 88 \0.0001
Female 5 601/652 0.01 [-0.02, 0.03] 0.68 93 \0.0001
Male 4 317/361 -0.01 [-0.04, 0.02] 0.44 79 0.003
The weighted mean difference estimates of BMD were calculated as DerSimonian and Laird estimators using random effects models
Tests for heterogeneity were performed by applying the Cochran Q test
Fig. 2 Forest plot for mean
femoral neck bone mineral
density. Difference in means (g/
cm
2) and 95% conﬁdence
interval for femoral neck bone
mineral density between
comparison groups with and
without Type 2 Diabetes
Mellitus, stratiﬁed per study and
gender. Diamonds represent
joint estimate for subgroups of
available studies for women
(upper) and men (middle),
respectively. Pooled estimate
for all studies displayed with the
diamond at the bottom
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123Fig. 3 Forest plot for mean hip
bone mineral density.
Difference in means (g/cm
2)
and 95% conﬁdence interval for
hip bone mineral density
between comparison groups
with and without type 2 diabetes
mellitus, stratiﬁed per study and
gender. Diamonds represent
joint estimate for subgroups of
available studies for women
(upper) and men (middle),
respectively. Pooled estimate
for all studies displayed with the
diamond at the bottom
Fig. 4 Forest plot for mean
spine bone mineral density.
Difference in means (g/cm
2)
and 95% conﬁdence interval for
spine bone mineral density
between comparison groups
with and without type 2 diabetes
mellitus, stratiﬁed per study and
gender. Diamonds represent
joint estimate for subgroups of
available studies for women
(upper) and men (middle),
respectively. Pooled estimate
for all studies displayed with the
diamond at the bottom
Fig. 5 Forest plot for mean
forearm bone mineral density.
Difference in means (g/cm
2)
and 95% conﬁdence interval for
forearm bone mineral density
between comparison groups
with and without type 2 diabetes
mellitus, stratiﬁed per study and
gender. Diamonds represent
joint estimate for subgroups of
available studies for women
(upper) and men (middle),
respectively. Pooled estimate
for all studies displayed with the
diamond at the bottom
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123level [88], reason why the diabetic status is needed to be
considered in risk fracture algorithms [89, 90].
Conclusion
Our meta-analysis showed that diabetic individuals have
higher BMD levels than non-diabetics independent of the
skeletal site of measurement, gender, age, BMI or medi-
cation use. In addition, by applying a meta-regression we
could establish that younger age, male gender, higher BMI
and higher HbA1c are positively associated with higher
BMD levels in diabetic individuals. The potential mecha-
nisms underlying these associations remain complex sug-
gesting that several inﬂuential factors need to be
considered while interpreting the association between
T2DM and BMD. Large prospective studies are needed to
establish the mechanisms underlying this association, and
most importantly the relationship with fracture risk, the
most adverse consequence of osteoporosis.
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